학술논문

A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m(2)) and autologous transplantation (MEL200) in newly diagnosed myeloma patients
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2010, 28 15, 1p. Supplement: S
Subject
Language
English
ISSN
15277755